REDHAWK RECEIVES PRE-MARKET CLEARANCE
FOR NEEDLE DESTRUCTION UNIT
October 25, 2016
Youngsville, Louisiana – RedHawk Holdings Corp. (OTCQB: IDNG) (“RedHawk” or the “Company”) announced today it has completed the re-engineering of its Sharps and Needle Destruction Device (“SANDD”) and has received pre-market clearance from the U.S. Food and Drug Administration for the sale of SANDD in the United States. RedHawk Medical Products, LLC, a wholly-owned subsidiary of RedHawk, acquired the tangible and intangible property rights to SANDD (formerly known as the Disintegrator™ Insulin Needle Destruction Unit) in December 2015.
The Company said initial manufacturing of the SANDD units has commenced and it expects deliveries and sales of SANDD to begin during the quarter ending December 31, 2016. Marketing of SANDD will initially be focused on the United Kingdom and the Middle East countries. Deliveries and sales in the United States are expected to begin during the three month period ending March 31, 2017.
SANDD is a portable, battery operated, insulin-needle destruction device primarily used by diabetics at home or in small hospital and clinical settings. The device is intended for the safe and environmentally friendly disposal of 27-30 gauge insulin hypodermic needles that are 5/16 to 1/2 inch in length. It can be used with most insulin pens with disposable insulin syringes from 1/3 to 1 cubic centimeter in volume. SANDD is an effective alternative to hazardous waste needle disposal utilizing sharps containers.
# # #